Full-Time

Associate Director

Drug Substance Development & Manufacturing

Entrada Therapeutics

Entrada Therapeutics

201-500 employees

Develops intracellular therapeutics using endosomal escape

Compensation Overview

$172k - $202k/yr

Remote in USA

Remote

US-based remote role with preference for New England candidates. Requires monthly or quarterly travel to Boston, MA headquarters.

Category
Biology & Biotech (2)
,
Required Skills
Supply Chain Management
FDA Regulations
Requirements
  • Master’s or suitable advanced degree in organic chemistry or another scientific or engineering discipline.
  • Minimum of 8 years of related experience in the pharmaceutical industry.
  • Demonstrated proficiency in process development, technology transfer, scale-up, and Good Manufacturing Practice manufacturing of drug substances for clinical and commercial supplies.
  • Proficiency in managing activities and resolving manufacturing challenges at Contract Development and Manufacturing Organizations during routine current Good Manufacturing Practice manufacturing and process validations.
  • Experience onboarding, managing, and collaborating with Contract Development and Manufacturing Organizations, raw material suppliers, testing partners, and other production partners.
  • Demonstrated ability to develop and maintain production timelines and budgets.
  • Knowledge of current industry practices and regulations including Good Practice, International Organization for Standardization, and International Council for Harmonisation across multiple health authorities such as the Food and Drug Administration and European Medicines Agency.
  • Ability to interpret and relate Quality standards for implementation and review.
  • Ability to communicate clearly and professionally both in writing and verbally.
  • Ability to travel up to 20 percent both domestically and internationally.
  • Ability to travel at least monthly or quarterly to the headquarters in Boston, Massachusetts.
Responsibilities
  • Lead and manage late-stage drug substance development for novel pipeline programs.
  • Facilitate timely execution, disposition, and release of intermediate and drug substance batches through technical review of master batch records, executed batch records, and other current Good Manufacturing Practice documentation.
  • Partner with internal and external Quality Assurance, Quality Control, and Technical Operations teams to execute late-stage development activities such as Process Characterization and Process Performance Qualifications.
  • Act as a person-in-plant for the execution of critical manufacturing activities for clinical and commercial batches.
  • Conduct risk assessments and develop mitigation strategies for manufacturing-related issues.
  • Identify and resolve manufacturing issues and escalate to internal or joint governance as required.
  • Implement and manage the Continuous Process Verification program to ensure manufacturing processes remain in control and meet validated parameters.
  • Author and review change controls to introduce process improvements through the program lifecycle from Phase 1 through validation and commercialization.
  • Collaborate with internal functions including chemistry, analytical, quality control, quality assurance, drug product, and regulatory affairs.
  • Partner with the team for Contract Development and Manufacturing Organization due diligence during selection to evaluate capabilities, risks, and required investments.
  • Author and review related sections in regulatory filing documents such as Investigational New Drug, Investigational Medicinal Product Dossier, New Drug Application, Biologics License Application, and Marketing Authorization Application.
Desired Qualifications
  • Hands-on experience in Solid Phase Peptide Synthesis, Solid Phase Oligonucleotide Synthesis, downstream purification, and lyophilization.
  • Residency in the New England region.
  • Strong project management and problem-solving skills.

Entrada Therapeutics focuses on developing a new class of medicines to treat devastating diseases by delivering therapies inside cells. Its core technology, the Endosomal Escape Vehicle (EEV) platform, helps drugs escape from endosomes—cellular compartments that often trap or degrade treatments—so they can reach intracellular targets. The product pipeline centers on EEV-therapeutics, including candidates for Duchenne muscular dystrophy and other neuromuscular diseases, with ENTR-601-45 currently cleared by UK and EU regulators to begin clinical trials. What sets Entrada apart is its explicit emphasis on enabling intracellular delivery to access targets that were previously hard to treat, using a platform-agnostic delivery approach that can work with a range of therapeutics such as oligonucleotides. The company’s goal is to advance multiple EEV-therapeutics through clinical development to address rare and other hard-to-treat diseases and reach patients who need new treatment options.

Company Size

201-500

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • ELEVATE-45-201 and Cohort 2 data by end-2026 could demonstrate dose-dependent dystrophin improvements.
  • Early functional benefit signal in Time to Rise velocity suggests clinical relevance beyond biomarkers.
  • $255M cash runway extends operations into Q3 2027, enabling multiple trial readouts.

What critics are saying

  • ENTR-601-44 Cohort 1 achieved only 2.36% dystrophin increase versus 10% investor expectations.
  • Sarepta's Elevidys dominates DMD market with $400M+ 2025 sales and proven efficacy.
  • Cash burn of $39.7M quarterly forces dilutive fundraising or R&D cuts within 18 months.

What makes Entrada Therapeutics unique

  • EEV platform enables intracellular delivery to previously undruggable targets across multiple organs.
  • Multi-exon DMD pipeline (44, 45, 50, 51) addresses broader patient population than competitors.
  • Vertex partnership validates EEV platform for myotonic dystrophy type 1 co-development.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Entrada Therapeutics who can refer or advise you

Benefits

401(k) Company Match

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Stock Options

Company Equity

Wellness Program

Mental Health Support

Gym Membership

Conference Attendance Budget

Professional Development Budget

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

1%
The Manila Times
Feb 4th, 2026
Entrada Therapeutics to Present at Upcoming Investor Conferences

Entrada Therapeutics to present at upcoming investor conferences. By GlobeNewswire February 4, 2026 BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026 Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, February 11, 2026, at 4:00 p.m. Eastern Time in New York, NY. TD Cowen 46th Annual Health Care Conference Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Tuesday, March 3, 2026, at 2:30 p.m. Eastern Time in Boston, MA. Live webcasts will be available on the Investor Relations section of the Company's website at www.entradatx.com. Replays will be available on the Entrada website for 90 days following the events. About Entrada Therapeutics Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV(TM)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular, ocular and other diseases, leveraging next-generation EEVs, novel oligonucleotide sequences and an advanced protein engineering platform. The Company's lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Investor Contact Karla MacDonald Chief Corporate Affairs Officer Media Contact Megan Prock McGrath CTD Comms, LLC

Stock Titan
Sep 2nd, 2025
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

DMDHelp
Aug 7th, 2025
Entrada Therapeutics doses first participant in Exon 44 skipping program; provides updates to other exon-skipping programs

Entrada Therapeutics, which received early funding from CureDuchenne, has provided updates on the status of several exon skipping programs.

The Manila Times
Feb 27th, 2025
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Entrada Therapeutics reports Fourth Quarter and Full Year 2024 Financial Results.

MarketBeat
Nov 28th, 2024
Massachusetts Financial Services Co. MA Invests $1.11 Million in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

MA invests $1.11 million in Entrada Therapeutics, Inc. (NASDAQ:TRDA).